EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles

Daiki Omata iD, Eigo Kawahara, Lisa Munakata, Hiroki Tanaka, Hidetaka Akita iD, Yasuo Yoshioka iD, Ryo Suzuki iD

Molecular Pharmaceutics · 04.11.2024 · 21 (11) · 5672-5680

DOI: 10.1021/acs.molpharmaceut.4c00628 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 26.09.2024. Verfasst von Daiki Omata und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Drug and Gene Delivery Research, Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo 173-8605, Japan. Hauptthemen laut MEDLINE: Nanoparticles, Polyethylene Glycols, Ovalbumin, RNA, Messenger. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Science Foundation, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticle-encapsulated mRNA (mRNA-LNP) vaccines have been approved for use to combat coronavirus disease 2019 (COVID-19). The mRNA-LNPs contain PEG-conjugated lipids. Clinical studies have reported that mRNA-LNPs induce the production of anti-PEG antibodies, but the anti-PEG antibodies do not affect the production of neutralizing antibodies. However, the detailed influence of anti-PEG antibodies on mRNA-LNP vaccines remains unclear. Therefore, in this study, we prepared ovalbumin (OVA) as a model antigen-encoding mRNA-loaded LNP (mRNA-OVA-LNP), and we determined whether anti-PEG antibodies could affect the antigen-specific immune response of mRNA-OVA-LNP vaccination in mice pretreated with PEG-modified liposomes to induce the production of anti-PEG antibodies. After intramuscular (i.m.) injection of the mRNA-LNP, the anti-PEG antibodies did not change the expression of protein or induction of cytokine and cellular immune response but did slightly increase the induction of antigen-specific antibodies. Furthermore, repeated mRNA-LNP i.m. injection induced the production of anti-PEG IgM and anti-PEG IgG. Our results suggest that mRNA-LNP induces the production of anti-PEG antibodies, but the priming of the antigen-specific immune response of mRNA-LNP vaccination is not notably affected by anti-PEG antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesPolyethylene GlycolsOvalbuminRNA, MessengerAnimalsMiceLiposomesFemaleCOVID-19 VaccinesLipidsMice, Inbred BALB CSARS-CoV-2mRNA VaccinesCOVID-19Immunoglobulin MAntibodies, Neutralizing

Stichwörter der Autor:innen

anti-PEG antibodylipid nanoparticlemRNApolyethylene glycolvaccine

Substanzen

Polyethylene GlycolsLipid NanoparticlesOvalbuminRNA, MessengerLiposomesCOVID-19 VaccinesLipidsmRNA VaccinesImmunoglobulin MAntibodies, Neutralizing

Autor:innen und Institutionen

  • Laboratory of Drug and Gene Delivery Research, Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo 173-8605, Japan.
  • Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai City, Miyagi 980-8578, Japan.
  • Center for Advanced Modalities and DDS, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan.

ORCID-Profile: Daiki Omata, Hidetaka Akita, Yasuo Yoshioka, Ryo Suzuki

Förderung

  • Takeda Science Foundation
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Omata, D., Kawahara, E., Munakata, L., Tanaka, H., Akita, H., Yoshioka, Y., & Suzuki, R. (2024). Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles. Molecular Pharmaceutics, 21(11), 5672-5680. https://doi.org/10.1021/acs.molpharmaceut.4c00628

Vancouver

Omata D, Kawahara E, Munakata L, Tanaka H, Akita H, Yoshioka Y, et al. Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles. Molecular Pharmaceutics. 2024;21(11):5672-5680. doi:10.1021/acs.molpharmaceut.4c00628

BibTeX
@article{Omata2024,
  author = {Omata, Daiki and Kawahara, Eigo and Munakata, Lisa and Tanaka, Hiroki and Akita, Hidetaka and Yoshioka, Yasuo and Suzuki, Ryo},
  title = {Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {11},
  pages = {5672--5680},
  doi = {10.1021/acs.molpharmaceut.4c00628}
}
Kostenlos starten →